OR YEHUDA, Israel, December 7, 2021 / PRNewswire / – Restore Medical Ltd., a clinical-stage MedTech company that develops heart implants for the treatment of congestive heart failure (CHF), today announced promising preliminary results from the First- clinical trial. in-Human by ContraBand â¢, a breakthrough treatment for patients with CHF. Minimally invasive catheter-delivered implants are used to treat patients with chronic left ventricular failure, where the heart is unable to pump enough oxygen-rich blood through the body.
Restore Medical has successfully implanted ContraBand â¢ in its first patients at ZNA Medical Center in Middelheim, Antwerp, Belgium, followed by Kaplan Medical Center in Israel.
âThese early procedures are milestones in proving that ContraBand â¢ technology is both safe and effective for patients with heart failure,â said Gilad marom, CEO of Restore Medical. âThe positive impact this treatment can have on the millions of people with CHF cannot be underestimated. Not only will it transform the quality of life for treated patients, but it will also reduce the enormous financial burden that results from having patients under treatment. ”
The ContraBand â¢ is expected to relieve symptoms and improve patients’ quality of life by forcing the healthy right ventricle to assist the failing left ventricle. The function of implants is completely reversible even long after the procedure, which is unique in the field of cardiovascular implants.
CHF is a progressive and debilitating disease and is a leading cause of death, with less than half of patients surviving five years after diagnosis and only 30% surviving ten years. With 25% of patients returning to hospital within one month of discharge, it is also the leading cause of rehospitalization. CCI affects tens of millions of people worldwide, including 6.2 million in United States alone, and is considered the greatest unmet clinical and financial need facing global health systems.
About Restore Medical Ltd.
Restore Medical has developed new technology that restores the geometry of failed hearts to improve the quality of life for patients. The company, led by the CEO Gilad marom, was created in 2015 by Dr. Elchanan Bruckheimer (Medical Director), Aaron Feldman (board member) and Stephane Bellomo (VP, Clinical Affairs). The main investors are Incentive Incubator, Peregrine Ventures, Allegro and a strategic investor. Today, the Restore Medical team includes top clinicians, engineers and top specialists with extensive knowledge and experience in the development of implantable cardiovascular devices and the commercialization of such devices.
For more details :
Amir Ben Artzi, [emailÂ protected]
Meirovitch Public Relations Agency
SOURCE Restore Medical Ltd.